A Phase I Study of AG-348 in Healthy Volunteers

NCT ID: NCT02108106

Last Updated: 2014-10-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-03-31
• Study Completion Date: 2014-08-31

Brief Summary

This is a dose escalation study that will be conducted in healthy volunteers. Multiple cohorts of volunteers will receive ascending oral doses of AG-348 to evaluate the safety and tolerability of a single oral dose of AG-348, the pharmacokinetics (PK) of a single dose of AG-348, and the pharmacodynamic profile of AG-348 with specific biomarkers assessed in the blood.

Conditions

Healthy Volunteer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

AG-348

Single oral dose of AG-348

Group Type: EXPERIMENTAL

AG-348

Intervention Type: DRUG

A range of doses of AG-348 will be tested based on assessment of safety and tolerability.

Placebo

Single oral dose of placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Interventions

AG-348

A range of doses of AG-348 will be tested based on assessment of safety and tolerability.

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Other Intervention Names

AG-348 will be administered as a single oral dose on Day 1.; Placebo will be administered as a single oral dose on Day 1.

Eligibility Criteria

Inclusion Criteria

• Healthy adult male or female subjects 18 - 60 years, in good general health who are able to understand consent and complete all study procedures.
• Female subjects of non-child bearing potential (surgically sterile or post-menopausal as confirmed by age [over 50 years], amenorrhea for 12 consecutive months and FSH).
• Male subjects who are not vasectomized must agree to use contraception up to 30 days after dosing.
• Subjects with body weight ≥50 kg; BMI ≥18.5 and ≤32 kg/m2.
• Subjects who are non-smokers and have not used nicotine containing products for at least 3 months prior to screening.
• Subjects must be willing to refrain from caffeine- or xanthene containing products (chocolate) prior to dosing through 72 hours after dosing.
• Subjects must agree to refrain from strenuous exercise prior to admission through final visit.
• Subjects must refrain from use of alcohol starting 7 days prior to admission through final visit.
• Subjects must agree not to donate blood products for duration of study participation.

Exclusion Criteria

• Subjects who have previously received AG-348.
• Subjects with clinically relevant screening laboratory tests.
• Female subjects of childbearing potential.
• Male subjects with QTcF interval ECG > 450 msec,or female subjects with QTcF interval ECG > 470 msec.
• Subjects with a history of a serious mental illness.
• Subjects with a clinically relevant medical history or pre-existing medical condition that would interfere with the absorption, metabolism or excretion of the study drug.
• Subjects with a history of any primary malignancy (cancer). Exceptions are certain skin cancers, cervical cancer in situ or other cancers that have been curatively treated without evidence of disease for a minimum of 1 year.
• Subjects with glucose-6-phosphate-dehydrogenase (G6PD) deficiency.
• Subjects who are positive for hepatitis B, hepatitis C or HIV.
• Subjects who have undergone surgery 6 months prior to screening.
• Subjects who have a history of illicit drug use or alcoholism within the last year.
• Subjects who are participating in other concurrent clinical trial of an investigational drug, or have received another investigational agent within the last 2 months.
• Subjects with any conditions which would make the subject unsuitable for enrollment, or could interfere with the subject's participation in or completion of the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Agios Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Samuel Agresta, MD, MPH & TM

Role: STUDY_DIRECTOR

Agios Pharmaceuticals, Inc.

Locations

Baltimore, Maryland, United States

Countries

United States

References

Yang H, Merica E, Chen Y, Cohen M, Goldwater R, Kosinski PA, Kung C, Yuan ZJ, Silverman L, Goldwasser M, Silver BA, Agresta S, Barbier AJ. Phase 1 Single- and Multiple-Ascending-Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers. Clin Pharmacol Drug Dev. 2019 Feb;8(2):246-259. doi: 10.1002/cpdd.604. Epub 2018 Aug 9.

Reference Type: DERIVED

PMID: 30091852 (View on PubMed)

Other Identifiers

AG348-C-001

Identifier Type: -

Identifier Source: org_study_id